河南省科学院高新技术研究中心首席科学家、归国博士安浩云 □记者 李红 实习生 张江舣 文 记者 李康 图
在河南省科学院高新技术研究中心首席科学家、归国博士安浩云的实验室里，有两样“宝贝”——高效液相色谱、高分辨质谱仪。抗艾新药阿滋福啶，就从这里诞生。
昨天下午1时许，安浩云刚从北京飞回来，就被记者拦在了实验室外，一聊就是好几个小时。他说，5年后，患者有望用上这种新药，价格比市面上的药低。
“海归”回家：我愿为家乡效力
3月28日，到河南省科学院高新技术研究中心调研的卢展工，听说归国博士安浩云研发出一种抗艾滋病新药，卢展工非常欣喜。安浩云说，卢书记的称赞让他“备受鼓舞”。
“我是河南人，又是郑大培养的，我愿意为家乡效力。”安浩云说。带着这个心愿，2010年，他入选河南省首批引进海外高层次人才“百人计划”回国工作，任河南省特聘专家、河南省科学院高新技术研究中心首席科学家、研究员，领导高效、低毒核苷类抗病毒和抗肿瘤创新药的研发工作。
专家档案
今年50多岁的安浩云，清瘦儒雅，毕业于郑州大学，师从吴养洁院士。1988年赴美留学后，在美国杨伯翰大学用3年零8个月获得博士学位，创下该校有史以来最快速度。又在美国弗吉尼亚大学进行药物合成的博士后研究。随后在美国几家著名药业公司从事新药研发工作，曾主持研发了抗肿瘤创新药——氟莱哌素等5个一类创新药，获得19项美国授权专利。
5年后，有望用上抗艾新药
“全球大概有10种抗艾药物，我国在这个领域还是空白。”安浩云说，“一位国际抗艾专家曾说，如果10年内，医学界仍然无法找到更好的抗艾药物，一半以上的艾滋病毒感染者都将面临死亡。”
自去年6月回到河南后，安浩云和他的团队的工作重心便放在研究抗艾药物上。“核苷类新药主要是用来抗病毒和抗肿瘤，河南省在这个药物类型领域里，基础不错，但河南目前还没有自主研制的新药。有了这个工作平台，我们争取有零的突破。”
“这可是我的大宝贝，(价值)150多万，我们的药物合成好后，都要用这个仪器进行分析，得出结果。”安浩云指着实验室里的一台高分辨质谱仪说，“目前，第一步合成阶段已完成，现在是临床前研究开发阶段，争取两年之内进入临床试验，三期临床试验之后就能进入市场。五年后，患者有望用上这种新药。”
有了它，昂贵的抗艾药肯定“低头”
据了解，目前的抗艾新药仅对一部分患者有效，大部分患者疗效小，因为许多人体内的病毒开始变异，产生抗药性，所以一般都需要把三四种药配合起来用，价格高昂，一个病人一年需要花几十万元，而且效果有限。
而安浩云研发的抗艾新药阿滋福啶，在北京、上海、美国杜克大学和美国北卡州的专业检测机构检测后，对一般艾滋病病毒的疗效要高于现在药物疗效的50～100倍；对耐药性艾滋病病毒的疗效要高于现在药物疗效的1万多倍。“这个检测结果让我们很受鼓舞。”安浩云说。
未来进入市场后，这种新药的价格会是多少呢？“具体价格，由相关部门制定。但有一点可以肯定，那就是，一定会比现在市面上6种抗艾药物的价格都要低。”安浩云说。
不仅抗艾新药，安浩云领军的团队还要继续研发出抗乙型肝炎病毒创新药、核苷类抗肿瘤新药和小分子抗肿瘤新药等。
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 |
| |
|
|
Henan AIDS drug research and development can benefit patients after 5 years http://www.sina.com.cn 2011 年 04 月 02 日 04:50 big river - Dahe
High-tech Research Center, Henan Academy of Sciences, Chief Scientist, Dr. An Haoyun returned
□ intern reporter Li Kang Li Zhangjiang outfitting map text reporter
High-tech Research Center, Henan Academy of Sciences in the chief scientist, Dr. An Haoyun returned to the laboratory, there are different "Baby" - high performance liquid chromatography, high resolution mass spectrometer. Popular anti-AIDS drug Azi Fu, born from here.
1 o'clock yesterday afternoon, An Haoyun flew back from Beijing, he was a reporter stopped at the lab, talk for several hours. He said that 5 years later, the patient is expected to spend this new drug, lower drug prices than the market.
"Returnees" to go home: I am willing to effect home
March 28, to the high-tech Research Center, Henan Academy of Sciences Lu Zhangong research, I learned that Dr. An Haoyun returned an anti-AIDS drug developed, Lu Zhangong very pleased. An Haoyun said Lu Shuji praise for his "inspired."
"I'm from Henan Province, Zheng Taipei raised again, I would like for the home effect." An Haoyun said. With this wish in 2010, he was elected to the introduction of Henan Province, the first high-level talent from overseas, "Hundred" to return to work, he served as ad hoc experts in Henan Province, Henan Academy of Sciences, chief scientist of high-tech research centers, researchers, leading efficiency, low toxicity nucleoside anti-virus and anti-tumor research and development of innovative drugs.
Expert File
An Haoyun, 50-year-old, lean elegance, graduated from Zhengzhou University, where he studied Yang-Jie Wu Academy of Sciences. After studying in the U.S. in 1988, Brigham Young University in the U.S. with 3 years and 8 months, received his Ph.D. in the history of the school set the fastest speed. And the University of Virginia in the U.S. post-doctoral research in drug synthesis. Followed by several well-known pharmaceutical companies in the United States engaged in drug research and development, has presided over development of innovative antitumor drugs - factors such as fluoride Levin piperazine 5 a class of innovative medicines, access to 19 U.S. patents.
5 years later, anti-AIDS drugs are expected to spend
"Global objects about 10 Kangai Yao, China in this field is blank." Anhao Yun said, "an international anti-AIDS experts said that if in 10 years, the medical community still can not find a better Kangai Yao objects, more than half HIV-infected persons will face death. "
Since last June, after back to Henan, Anhao Yun and his team will focus on research material on the Kangai Yao. "Nucleoside class of drugs is primarily used anti-virus and anti-tumor drug types in this area in Henan Province, the foundation is good, but there is no independent research and Henan, a new drug. With this work platform, we strive for zero breakthrough. "
"This is my big baby, (worth) more than 150 million, our drug synthesis is completed, should use this instrument to analyze the outcome." An Haoyun pointing lab, said a high-resolution mass spectrometer "At present, the first synthesis stage has been completed and is now the pre-clinical research and development stage, seek to enter clinical trials within two years, after Phase III clinical trials will be able to enter the market. Five years later, the patient is expected to spend this new drug. "
With it, expensive Kangai Yao yes "bow"
It is understood that only part of the anti-AIDS drugs in patients, the majority of patients with small effects, because many people start the virus mutation, drug resistance, it is generally necessary to tie up with three or four drugs, the high price of a patients need to spend several hundred thousand dollars a year, but limited effect.
The anti-AIDS drug research and development An Haoyun A Zifu pyridine, in Beijing, Shanghai, Duke University and North Carolina State after a professional testing organizations, the general efficacy of HIV drug efficacy than is now 50 to 100 times; on the efficacy of HIV drug resistance than drug efficacy are now 1 million times. "The test results so we are very encouraged." An Haoyun said.
Coming into the market, the price of this new drug will be how much? "Specific price, by the relevant department. But one thing is certain, that is, bound to material now available in the market price of 6 Kangai Yao is lower." An Haoyun said.
Not only anti-AIDS drug, An Haoyun leader of the team should continue to develop innovative drugs against hepatitis B virus, nucleoside analogues and small molecule anti-tumor drugs such as anti-tumor drugs.
